Dallas, TX (PRWEB) January 18, 2014
Despite the launch of Spectrum Pharmaceuticals’ EOquin, Nominal Growth in US and EU Bladder Cancer Market is expected from 2012 to 2017.
This report estimates the bladder cancer market in the US and 5EU (France, Germany, Italy, Spain, and UK) in 2012 to be valued at $239.3m. This market is defined as the sales of branded drugs, including Valstar (US only) and Javlor (Europe only), and major generics regimens across both markets. Predominantly due to the higher price of drugs, the majority of sales were generated in the US market, $139.4m (58%), with EU sales estimated to be $99.8m (42%).
By the end of the study period in 2017, GlobalData forecasts global sales in the bladder cancer market to increase to $297.5m, at a compound annual growth rate (CAGR) of 4%. The majority of sales at this point will still come from the US, with $181.1m (61%), with its market share increasing marginally from 58% in 2012 to 61% by the end of the forecast period. Overall, GlobalData expects an increase in market size primarily due to a forecast increase in number of incident cases across the study period in the 6MM and the entrance of EOquin into the market during the forecast period.
Complete report is available at http://www.marketoptimizer.org/opportunityanalyzer-bladder-cancer-opportunity-analysis-and-forecasts-to-2017.html.
The emergence of Spectrum Pharmaceuticals’ EOquin, the only product in the pipeline to enter the market during the forecast period, will also have a small incremental effect on the bladder cancer market. Global sales for EOquin will account for $13.2m in its launch year, 2016, and $26.1m in 2017, accounting for 8.8% of sales in that year.
There are several major drivers of the bladder cancer market in the US and 5EU.
There will also be some barriers to the growth of the bladder cancer market in the US and 5EU.
High Unmet Needs Exist Across the Different Patient Populations
Interviewed experts report the level of unmet need in the bladder cancer market to be high, both in the early-stage, non-muscle invasive bladder cancer (NMIBC) and the late-stage muscle-invasive and metastatic settings. Little progress has been made over the past 10 years that has significantly changed the treatment algorithm for patients or provided more efficacious treatment options. GlobalData has identified better cure rates for NMIBC patients to be one of the key unmet needs.
Purchase a copy of this report at http://www.marketoptimizer.org/contacts/purchase?rname=4681.
Browse more reports on Pharmaceuticals Market at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals.
Contact sales(at)marketoptimizer(dot)org for further information.
MarketOptimizer.org (http://www.marketoptimizer.org/) is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.